MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall
First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cou...
26 Maj 202315min
MPR Weekly Dose 160 — Labeling Update for Prescription Stimulants; Veozah Approved for Vasomotor Symptoms; FDA Vote on DMD Therapy; Fungal Meningitis Cases in US; Child's Smart Thermometer Recalled
FDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne m...
19 Maj 202311min
MPR Weekly Dose 159 — OTC Birth Control Pill Switch; First Tx for Agitation Associated With Dementia; Fabry Disease Treatment; Farxiga Approval Expanded; Contaminated COVID-19 Tests
Panel votes unanimously in favour of over-the-counter change for contraceptive pill; First pharmacological therapy for agitation associated with dementia due to Alzheimer disease; Elfabrio approved fo...
12 Maj 202313min
MPR Weekly Dose 158 — Early Alzheimer Treatment; First RSV Vaccine; Narcolepsy Tx; Toilet Seat That Monitors Health; FDA Ammonia Warning
Investigational treatment for early Alzheimer disease shows promise; First vaccine for the prevention of lower respiratory tract disease caused by RSV; Nightly granules approved for narcolepsy; Latest...
5 Maj 202312min
MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert
Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery sys...
28 Apr 202310min
MPR Weekly Dose 156 — Bivalent COVID-19 Vaccines; Vote on Agitation With Alzheimer Dementia Tx; Descheduled Drug; Migraine Tx Expansion; Restless Legs Syndrome Device
Updates to COVID-19 vaccines; FDA panel votse on potential treatment for agitation with Alzheimer dementia; DEA deschedule drug; Migraine treatment indication expanded; A new device is cleared to aid ...
21 Apr 202311min
MPR Weekly Dose 155 — Knee Shock Absorber; Opioid Label Updates; Imbruvica Indications Withdrawn; Patch for Excessive Sweating; Polyclonal Tx for Flu
Implantable device approved for those with knee osteoarthritis; Prescribing Information labeling updated for opioids; Imbruvica indications withdrawn; Patch to combat excessive underarm sweating given...
14 Apr 202313min
MPR Weekly Dose 154 — Novel COVID-19 Tx Granted EUA; Makena Withdrawn; Infant Supine Sleep System; Padcev Plus Keytruda Approved; Opioid Mail-Back Envelopes, Respiratory Depression Detection Device
Treatment granted Emergency Use Authorization for hospitalized COVID-19 patients; Preterm-birth prevention treatment withdrawn from market; Sleep device for infants gets green light for marketing; New...
7 Apr 202315min
